1-(2-Phenoxyethyl)imidazol | 30170-83-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 1-(2-Phenoxyethyl)imidazol
• 英文别名: 1H-Imidazole, 1-(2-phenoxyethyl)-；1-(2-phenoxyethyl)imidazole
• CAS: 30170-83-3
• 化学式: C₁₁H₁₂N₂O
• mdl: MFCD03010825
• 分子量: 188.229
• InChiKey: INUSBZKZIYQSRM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.181
• 拓扑面积：
  27
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(2-Phenoxyethyl)imidazol 在 sodium iodide 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 反应 122.0h， 生成 [Ir(CH₃CN)₂(I)₂{κ²C,C′-(methylenebis(N,N′-bis(2-phenoxyethyl)imidazol-2-ylidene))}]BF₄
  参考文献：
  名称：

  Hydrolysis and Methanolysis of Silanes Catalyzed by Iridium(III) Bis-N-Heterocyclic Carbene Complexes: Influence of the Wingtip Groups

  摘要：

  New [Ir(CH3CN)(2)(I)(2){kappa C,C'-bis(NHC)}]BF4 complexes featuring bis-NHC ligands with a methylene bridge and different N substitution (-CH2,CH2CH2CH3. and -CH2CH2OPh) were synthesized. NMR studies and X-ray diffraction structures evidenced that the wingtip group -CH2CH2OPh presents a hemilabile behavior in solution, with the oxygen atom coordinating and dissociating at room temperature, which contrasts with the strong coordination of the ether functions in the complex [Ir(I)(2){kappa C,C',O,O'-bis(NHCOMe)}]BF4 (bis(NHCOMe) = methylenebis(N,N'-bis(2-methoxyethyl)imidazol-2-ylidene)), previously reported by us. These complexes proved to be efficient catalysts for the hydrolysis and methanolysis of silanes, affording molecular hydrogen and silyl alcohols, or silyl ethers as the main reaction products in excellent yields. The hydrogen generation rates were very much dependent on the nature of the hydrosilane and the coordination ability of the wingtip group. The latter also played a key role in the recyclability of the catalytic system.

  DOI：

  10.1021/om5011726
• 作为产物：
  描述：

  咪唑 、 2-苯氧乙基溴 在 sodium hydride 作用下， 以 四氢呋喃 为溶剂， 生成 1-(2-Phenoxyethyl)imidazol
  参考文献：
  名称：

  1-[(Aryloxy)alkyl]-1<I>H</I>-imidazoles as Inhibitors of Neuronal Nitric Oxide Synthase

  摘要：

  DOI：

  10.1211/146080899128735225

文献信息

• N-(phenoxyalkyl)imidazoles as selective inhibitors of the thromboxane
  申请人：Pfizer Inc.

  公开号：US04602016A1

  公开（公告）日：1986-07-22

  N-(mono or disubstituted phenoxyalkyl)imidazoles and the pharmaceutically acceptable acid addition salts thereof are able to selectively inhibit the action of the thromboxane synthetase enzyme without significantly inhibiting the action of the prostacycline synthetase or cyclooxygenase enzymes and are thus useful in the treatment of ischaemic heart disease, stroke, transient ischaemic attack, thrombosis, migraine, and the vascular complications of diabetes.

  N-(单取代或双取代苯氧烷基)咪唑及其药用可接受的酸盐能够选择性地抑制血栓素合成酶酶的作用，而不显著抑制前列环素合成酶或环氧化酶酶的作用，因此在缺血性心脏病、中风、短暂性缺血发作、血栓形成、偏头痛以及糖尿病的血管并发症治疗中是有用的。
• Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System
  申请人：Gupta Ajay

  公开号：US20110319459A1

  公开（公告）日：2011-12-29

  Disclosed are compounds of the general formula (I): TC n D  (I), compositions comprising an effective amount of said compounds either alone or in combination with other chemotherapeutic agents, and methods useful for treating or preventing cancer and for inhibiting tumour tissue growth. These compounds attenuate the oxidative damage associated with increased heme-oxygenase activity and can reduce cell proliferation in transformed cells. In addition, the described compounds and compositions are useful as neuroprotectants and for treating or preventing neurodegenerative disorders and other diseases of the central nervous system.

  本发明涉及一般式（I）的化合物：TCnD（I），包括单独使用或与其他化疗药物联合使用的有效量的该化合物的组合物，以及用于治疗或预防癌症和抑制肿瘤组织生长的有用方法。这些化合物减弱了与增加血红素氧合酶活性相关的氧化损伤，并可以减少转化细胞中的细胞增殖。此外，所述化合物和组合物可用作神经保护剂，并用于治疗或预防中枢神经系统的神经退行性疾病和其他疾病。
• N-SUBSTITUTED INDAZOLE SULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20150284389A1

  公开（公告）日：2015-10-08

  Disclosed are compounds of Formula A A and Formula A B : wherein “Heteroaryl-1”, R A1 , R A2 , R B1 , and R C are defined herein, which novel compounds have properties for blocking Na 1.7 ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formulae A A and A B or their salts, and methods of treating neuropathic pain disorders using the same.

  本发明涉及式AA和式AB的化合物：其中“Heteroaryl-1”，RA1，RA2，RB1和RC在此定义，这些新型化合物具有阻断周围和交感神经元中发现的Na 1.7离子通道的特性。还描述了包含式AA和AB或其盐的制药配方，以及使用它们治疗神经病理性疼痛障碍的方法。
• Imidazole derivatives and salts thereof, their synthesis, and pharmaceutical formulations
  申请人：THE WELLCOME FOUNDATION LIMITED

  公开号：EP0003560A2

  公开（公告）日：1979-08-22

  Pharmaceutical formulations comprising an imidazole (or pharmaceutically acceptable salt thereof) of formula: wherein (i) A is an aliphatic hydrocarbon residue of from 1 to 4 carbon atoms and R is a naphthyl, tetrahydronaphthyl, heterocyclyl, arylthio, arylalkylthio, aryloxy, arylalkyloxy, arylhydroxymethylene, arylcarbonyl, arylalkylcarbonyl, alkyloxy, alkylthio or a substituted cycloalkyl or cycloalkenyl group or (ii) A is a -S02- group and R is aryl or heterocyclyl or (iii) A is a chemical bond and R is a heterocyclyl or substituted phenyl group, or (iv) A is an aliphatic hydrocarbon residue of from 1 to 3 carbon atoms and R is a halophenyl group. Some of these imidazoles and salts are novel. Methods of preparing the imidazoles are disclosed. The imidazoles and their salts are useful in the treatment or prophylaxis of thrombo-embolic conditions.

  药物制剂，包含式中的咪唑（或其药学上可接受的盐）： 其中 (i) A 是 1 至 4 个碳原子的脂族烃残基，R 是萘基、四氢萘基、杂环基、芳硫基、芳烷硫基、芳氧基、芳烷氧基、芳羟甲基、芳羰基、芳烷基羰基、烷氧基、烷硫基或取代的环烷基或环烯基，或 (ii) A 是-S02-基团，R 是芳基或杂环基，或 (iii) A 是化学键，R 是杂环基或取代苯基，或 (iv) A 是 1 至 3 个碳原子的脂肪烃残基，R 是卤代苯基。 其中一些咪唑和盐是新型的。 这些咪唑的制备方法已经公开。咪唑及其盐类可用于治疗或预防血栓栓塞。
• Selective thromboxane synthetase inhibitors. 1. 1-[(Aryloxy)alkyl]-1H-imidazoles
  作者：Peter E. Cross、Roger P. Dickinson、M. John Parry、Michael J. Randall

  DOI：10.1021/jm00148a009

  日期：1985.10

  1-(2-Phenoxyethyl)-1H-imidazole was found to be an inhibitor of thromboxane (TxA2) synthetase, but it also inhibited the adrenal cytochrome P-450 enzyme steroid 11 beta-hydroxylase. The preparation of a series of analogues is described, and activity against TxA2 synthetase, PGI2 synthetase, cyclooxygenase, and steroid 11 beta-hydroxylase is discussed. Potency against TxA2 synthetase was increased by introduction of a carboxyl group at a suitable distance from the imidazole ring. A distance of 8.1-8.8 A between N-1 of the imidazole and the carboxyl carbon was found to be optimal. Introduction of a carboxyl group also had the effect of reducing activity against steroid 11 beta-hydroxylase. The most potent and selective compound was found to be 4-[2-(1H-imidazol-1-yl) ethoxy]benzoic acid (14).